In an evidence report published on Jan. 12, the Institute for Clinical and Economic Review said vision loss drug Luxturna voretigene neparvovec-rzyl from Spark Therapeutics Inc. (NASDAQ:ONCE) needs substantial discounts to be cost-effective.
The institute said while clinical evidence on Luxturna provides high
